The founder of 23andMe Research Institute wants to reach 100 million users, an ambitious goal after the seller of DNA testing kits emerged from bankruptcy as a nonprofit. 23andMe has the DNA of about ...
Bankrupt genetic-testing firm 23andMe agreed to sell its data bank, which once contained DNA samples from about 15 million people, to the drug developer Regeneron Pharmaceuticals for $256 million. The ...
DNA testing and genealogy companies are stepping up user account security by mandating the use of two-factor authentication, following the theft of millions of user records from DNA genetic testing ...
A nonprofit controlled by Anne Wojcicki, former chief executive of 23andMe, has won the bidding process to buy the bankrupt genetic testing company. If approved by the court, the sale would put ...
Hosted on MSN
23andMe users have until July 14 to file a claim in the DNA company's bankruptcy case. Here's how to do it.
Customers of the genetic testing company 23andMe have until July 14 to file a claim as part of a restructuring in its bankruptcy case. In filing a claim, eligible customers can seek compensation for ...
Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals’ offer for the DNA-testing company in a bankruptcy auction.
Valerie is a seasoned writer and editor who has spent her career creating content in the parenting and women's wellness spaces. Before joining Forbes Health, Valerie was the trending news editor at ...
Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday. Regeneron said it will comply with 23andMe’s privacy ...
Bankrupt genetic-testing firm 23andMe has agreed to sell its data bank, which once contained DNA samples from about 15 million people, to the drug developer Regeneron Pharmaceuticals for $256 million.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results